News

The first participant has been dosed in a clinical trial evaluating the long-term effects of Attruby (acoramidis), an approved treatment for transthyretin amyloid…

Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) should be treated as early as possible once a patient has symptoms and a confirmed disease-causing genetic mutation,…

Biopsies taken during surgery for carpal tunnel syndrome, a condition that affects a wrist nerve, may help with early detection of transthyretin cardiac…

Although mutations that cause hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) most frequently lead to nerve damage, they can also cause heart damage and other…

Enrollment is open in a post-marketing clinical trial designed to investigate whether long-term treatment with Attruby (acoramidis) can reverse heart disease-related changes in people…

A specific genetic variant may have contributed to signs of severe liver problems observed in a few patients given nexiguran ziclumeran (nex-z), an investigational gene-editing…

Regulatory authorities in the European Union (EU) have recommended approval of Tafamidis Accord, a generic version of Vyndaqel (tafamidis), an approved treatment for adults with hereditary…

A real-world study in Spain comparing two similar medications for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) showed greater benefits with the infusion therapy…

Women with transthyretin amyloid cardiomyopathy (ATTR-CM) had worse outcomes than men in a new study, but the gap may reflect differences in age and…

A type of cell damage called oxidative stress may be key to the development of disease symptoms in people who carry the most common TTR…